Cubist Pharmaceuticals Inc.’s President and Chief Operating Officer Robert Perez will succeed CEO Michael Bonney effective Jan. 1, making him responsible for completing the company’s expansion from a one-asset firm focused on the U.S. market to an international specialty pharma with a broad portfolio.
The leadership change, announced Oct. 20, comes at a transformative time for Cubist, which is launching several new antibiotics and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?